FAQ

neoplasm of uncertain malignant potential

Known as: Neoplasm of Borderline Malignancy, Neoplasm of Low Malignant Potential, NEOPLASMS OF UNCERTAIN BEHAVIOR 
A neoplasm displaying morphologic, phenotypic, or genotypic characteristics that are clearly not benign but do not permit the establishment of a… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1972-2018
05019722018

Related topics

Related topics

6 relations
LarynxNeoplastic CellNeurofibromatosesNeurofibromatosis 1
(More)

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
neoplasm of uncertain malignant potential
Neoplastic Cell
Larynx
Polycythemia Vera
Neurofibromatoses
Neurofibromatosis 2

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors.
Metabolites are the end products of cellular regulatory processes, and their levels can be regarded as the ultimate response of… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
OBJECTIVE Mutations of BRAF, a downstream mediator of K-RAS, have been described in serous borderline tumors of the ovary. Data… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with…
The infrequent association of serous borderline tumors (SBTs) with invasive serous carcinoma has led to the view that SBTs are… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.
The natural history, classification, and nomenclature of ovarian serous tumors of low malignant potential (S-LMP) (serous tumors… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.
Molecular genetic changes that are associated with the initiating stage of tumor development are important in tumorigenesis… (More)
  • figure 1
  • table 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas.
With the exception of benign cystadenomas, mucinous ovarian tumors are rare and heterogeneous neoplasms. They have been… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study.
PURPOSE Borderline tumors account for 10% to 20% of epithelial ovarian tumors, and their prognosis is outstanding; nevertheless… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'.
Mucinous ovarian neoplasms other than cystadenomas and adenofibromas have been classified as either borderline tumors or… (More)
Is this relevant?
1999
1999
Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns.
A group of investigators have proposed that the presence of micropapillary or cribriform patterns within ovarian serous tumors… (More)
Is this relevant?
Highly Cited
1996
Highly Cited
1996
Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases.
Poor outcome in serous borderline tumors (SBT) of the ovary is limited to patients with advanced stage disease. This study was… (More)
Is this relevant?